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Aims: The aim of this study is to assess the mutagenicity effect of occupational 
exposure to cytostatc in order to propose an environmental medical prevention 
program. 
Materials and Methods: A cross-sectional descriptive study was conducted for three 
months, it involved 39 nurses exposed to cytostatic drugs in oncology and 43 
referents. They were matched by age, sex, smoking, seniority .The data were 
collected using a medical questionnaire. Mutagenicity was evaluated by the Ames 
test. The calculation of the ICC has allowed the classification of exposure. 
Results: The average age of exposed subjects is 42.28 ± 9.90 years with female 
predominance. 75% of staff is classified exposure level 3 and 2. 
Among the contact with cytostatic drugs is associated with a risk of mutagenic 3 (RR 
= 3.28, 95% CI: 1.73, 6, 22) with a highly significant difference (P << 0 .0001). 60% 
of samples of exposed and 15% of referents were positive, the mean number of 
positive revertants was 527.94 with a good correlation between the number of 
revertants and the ICC. 
Conclusion: This study confirms mutagenic risk among nurses handling cytostatic 
without adequate safeguards. It encourages the alignment on best practices to improve 
working conditions in oncology structures. 
 
 
 
Introduction 
The first study showing evidence of genotoxicity in the personal care handling cytostatic was conducted on urine of 
nurses involved in the administration of chemotherapy in a Finnish oncology service using the Ames test [1]. 
 
And for over thirty studies were conducted. The majority of articles were published before the nineties. The results 
are controversial, in connection with numerous methodological problems (early urine collection after short exposure 
to drugs, drug intake, confounding factors, etc.) [2, 3, 4, 5, 6] .Divers authors recorded increased urine mutagenicity 
power among nurses handling these drugs without means of protection [1, 2.7, 8.9] and / or inappropriate. [10] 
Conversely, other studies have not revealed positive mutagenic activity [10,11,12,13,] .In certain situations, the 
interpretation of results is difficult and does not conclude with certainty the presence or absence of mutagenic 
activity (doubtful test) [14,15,16,17]. 
 
Since the publication of best practices for preparation and administration of cytostatic,  in several countries, this test 
was used to assess the effectiveness of preventive measures in particular the preparation in vertical or horizontal 
laminar flow hood. No mutagenic urine was highlighted for preparation of chemotherapy in vertical flow hood, 
conversely to the hood horizontal laminar flow. [18] The mutagenic activity of urine has been proposed by some 
authors for monitoring workers exposed to cytostatic. [19] 
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Our study aims was to assess the mutagenic risk among nurses exposed to cytostatic to outline an environmental 
medical prevention program. 
 
Materials And Methods 
A cross-sectional descriptive analytic study was conducted for three months from November 2014 to January 2015. 
It concerned 82 subjects: 39 nurses exposed to cytostatic of University Hospital center in eastern Algeria and 43 
referents. The two groups were matched for age, sex, smoking and seniority at the workplace. 
After their consent, each subject received medical questionnaire containing several topics (demographics and 
professionals, toxic habits, history, drug intake, power type), a clinical examination and a urine collection for Ames 
test. 
 
Evaluation of mutagenicity 
The evaluation of mutagenic cytostatic power was made by the Ames test. We used the TA 102 strain derived from 
Salmonella typhimurium LT2 strain carries a mutation in a gene coding for the synthesis of the amino acid histidine, 
this mutation renders the bacteria unable to grow on medium without histidine . The strain was stored at -80 ° C and 
regularly checked for genetic markers (tetracycline resistance, rfa mutation and UV sensitivity) . 
 
Protocol Ames test 
From a preserved strain, 20 μl of the strain are grown in 5 to 20 ml of nutrient broth supplemented with a histidine 
and traces of biotin and 25 g / ml of tetracycline. After 18 hours of incubation at 37 ° C in a shaking water bath, 100 
.mu.l of this culture are contacted with 100 µl of each dilution of the test molecule, and 500μl of buffer. The mixture 
is incubated at 37 ° C for 20 min. Two milliliters of top agar (0.6% agar and 0.6% NaCl) are added to the mixtures 
and paid after gentle agitation, on the minimum agar  (constitutes 1% of MgSO4, 10% citric acid, 50% of K2HPO4, 
17.5% of Na2NH2PO4-4H2O, 2% glucose, and 1.5% agar). After solidification of the mixture, the dishes are 
incubated at 37 ° C for 48 to 72 hours. Once the cans are removed from the incubator, colonies are counted and the 
results are expressed in the form of revertant colonies per plate [20]. 
 
Reading and interpretation of results: the visual counting is easy, unlike the stumps by number plate is less than 100, 
for strain TA 102; an increase of twice can be observed (more than 200) .The result of the Ames test is considered 
positive if the concentration tested for the number of revertants induced is equal to or greater than twice the number 
of spontaneous revertants. The validity of the test is ensured by the positive response obtained with the positive 
controls [21]. 
 
Assessment of exposure to cytostatic 
To assess the importance of contact with cytostatic drugs, we calculated the Index Contact Cytostatic (ICC), only 
parameter that currently evaluating simply exposure. It was calculated over a period of 15 days from the following 
formula: 
ICC = n R + nA / Nh 
• nR: number of preparations carried out by a person in a given period 
• nA: number of administrations carried out by the same person for a specified period. 
• nH: number of hours of presence of this person during the specified period. 
 
This index identifies three levels which are attached special precautions: 
• Level 1: ICC <1: preparation and administration occasionally, need for individual prevention. 
• Level 2: 1 <ICC <3: preparation and administration in moderate amounts, need for establishment of a 
collective prevention (security post cytostatic). 
• Level 3: ICC> 3: intensive preparation and administration, establishment of a centralized reconstruction 
unit. 
 
Statistic Study  
Data were entered and analyzed by software XL STAT 2015 and Mini Tab 16. 
Employees’ statistical tests for data analysis were: 
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• Comparison tests: t-test (comparison of two averages) and the z-test (comparison of proportions) and 
Anova 
• The association test: calculation of the relative risk (RR). 
 
P-value < 0.05 was considered statistically significant 
 
Results  
Sociodemographic and professional characteristics of the study population 
There is no significant difference between the exposed group and the group referred the matter concerning 
sociodemographic characteristics (age, sex, educational level and marital status) and professional (seniority). 
The exposed group consisted of 39 nursing relatively young with an average age 42.28 ± 9.90 years, female 
predominance (sex ratio =  0.21), the level of secondary education (80% ) and marital status "married. 
 
Calculation of the index contact cytostatic  
The medical oncology service was classified as level 3, while that of hematology was classified as Level 2. The 
pediatric oncology was classified as Level 1 (table 1). 
 
Table 1: Comparison of the ICC oncology structures (2014-2015) 
 Level  Average  Standard 
Deviation  
P-value 
Oncology 
 
3 8,83 1,47 0,000*** 
Hematology 
 
2 1,54 0,30 
Pediatric 
 
1 0,50 0,28 
 
Study of mutagenicity Ames test 
Two techniques were used for the interpretation of Ames test: the comparison with the negative control and the 
calculation of the average positive revertants in exposed and non-exposed. The results are similar for both methods, 
with a very highly significant difference. 
The Ames test was positive for 24 nurses exposed to cytostatic, versus, 15 unexposed. The relative risk of 3.28 (95% 
CI: 1.73, 6, 22), the difference was highly significant (P << 0 .0001). (Table 2) 
 
Table 2 :Association between exposure to cytostatic in a University Hospital centre in Eastern Algerian  and positivity the 
Ames test (2014-2015) 
 Exposed = 
39 
 
Referents=  
43 
RR IC 95% P-value 
Ames test   
(+) 
24 15 3,28 (1,73; 6,22) 0,000*** 
 
For the first method, 60% of samples of exposed subjects and 15% of non-exposed were positive (Table 3). 
For the second method, the average number of revertants was 527.94 ± 197.73 for exposed and 297.17 ± 90.34 for 
referents (Table 2). 
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Table 3: Comparison of results of the Ames test between exposed to cytostatic and  unexposed (2014-2015) 
Revertants + Minimum Maximum Average  SD  P-value 
Exposed  200.00 1000.00 527.94 197.73 0,000*** 
Referents 199.00 490.00 297.17 90.34 
Test Positive 
N                 % 
Negative 
N               % 
P 
Exposed 24 60 % 15 40 % 
 
0,000*** 
Referents 9 15% 34 85 % 
 
The distribution of results of mutagenicity by the level of CCI shows an association between the number of revertant 
and the ICC. The number of revertants increases with the number of preparations and administration of cytostatic 
drugs. It increased to 378.75 for level 1 to level 2 388.33 to 597.30 for level 3. This increase was highly statistically 
highly significant (p <0.001) (Table 3). 
 
Table 3: Breakdown of the Ames test results in exposed to cytostatic  by level of ICC (2014-2015) 
 
ICC 3 ICC0 ICC 1 ICC2 
Minimum 230.00 199.00 230.00 200.00 
Maximum 1000.00 490.00 490.00 480.00 
4 th Quartile 460.00 240.00 357.50 325.00 
Median 560.00 262.50 385.00 435.00 
3rd  Quartile 723.00 317.75 422.50 477.50 
Average  597.30 297.17 378.75 388.33 
Variance  38761.21 7958.34 5360.93 11147.22 
Standard deviation  200.77 90.34 78.27 115.65 
Standard deviation for the Average  39.37 14.28 27.67 47.21 
Lower bound average  (95%) 516.21 268.28 313.26 266.94 
upper bound average  (95%) 678.40 326.06 444.23 509.71 
 
Anova  F = 25,26   P= 0,000*** 
 
Discussion 
Nurses are exposed in the structures of Oncology to cytostatic during the preparation and administration of 
chemotherapy drugs. Sometimes, the exhibition is made after contact with excreta and vomit of patients. 
 
The study of working conditions has revealed the lack of separation between local preparation and administration, 
the importance of the workload (on average 70 procedures per day in the medical oncology service), the lack of 
means of collective protection (no hood or insulator) and inadequate personal protective equipment which were 
limited to gowns and gloves. Latex gloves are worn only by 26% of nurses. The workload was confirmed by 
calculating the ICC or 75% of nurses belonged to level  2 and 3 services. 
 
It is clear from our work that the risk of having a positive Ames test is three times higher in subjects exposed to 
cytostatic (RR = 3.28, 95% CI: 1.73, 6, 22) 
Sixty percent (60%) samples of exposed subjects, versus 15% of  un exposed were mutagenic. Our results coincide 
with those published in 2013 by Allaire who reported a positivity rate of referents in Ames test 10%. [22] 
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The results of our study converge to a strong association between exposure to cytostatic and positivity the Ames test. 
The average revertants is very high, it is 597.30 ± 200.77 with a parallel increase with the level of exposure to 
cytostatic. This result is explained by the importance of the workload, the lack of specific means of collective and 
individual protection and the number of drugs to prepare. Staff handle 9 mutagenic, 7 drugs are very dangerous 
(ifosfamide, gemcitabine, Camto, cyclophosphamide, dacarbazine, carboplatin, adriamycin), and two dangerous 
(Eloxatin, Bleomycin). Among the cytostatic, it is mainly alkylating substances with mutagenic and carcinogenic 
action, exposure index cyclophosphamide is 1. 
 
In our series, we recorded a highly significant difference; the same findings were reported in the literature to nurses 
and pharmacists preparing cytostatic unprotected. In a typical study exposed / unexposed, Benhamou evaluated the 
mutagenic cytostatic power by comparing 29 nurses preparing cytostatic drugs without special precautions and 29 
unexposed. The Ames test was positive with a statistically significant difference [2]. The same result was found by 
Pohlová et al studying the mutagenic cytostatic power in 39 exposed and 19 referents [23]. 
 
Similarly, Caudel et al in 1988, found significant results when performing the Ames test in nursing oncology 
services [8]. Identical findings were published by Clonfero et al (1989), Falck et al (1979) [9,1]. 
 
Similar results were observed in the manipulators cytostatic drugs, but without specifying the working conditions 
and the availability and wearing of protective equipment (Table) Roth (1995), Newman (1995) [23, 24].. 
 
Other authors found a urine mutagenicity of workers handling cytostatic under horizontal laminar flow hood. 
Thiringer (1991), reported the positivity of the Ames test in 60 nurses preparing courses of chemotherapy under a 
laminar flow hood [19]. It is the same for Anderson's conclusions in 1982 [ 18]. 
 
In the series of Kolmodin-Hedman , work under a hood and wearing gloves were insufficient to protect nursing 
mutagenic hazard cytostatic [10], 
 
Conversely our conclusions in some work, the mutagenic cytostatic power has not been confirmed (Table 4) 
 
Table 4:  Study of mutagenicity of the urine of workers exposed to cytostatic 
Authors  Population  Working Conditions  Results  Ref  
Rezaei(2013) Nurses  138 Pas de précision Positive  25 
Labuhn (1998) 
Nurses Pharmacists 
83/35 
No particular precaution Doubtful 17 
Demeo (1995) Nurses 38/25 
 
Doubtfull 35 
Roth (1995) Nurses Unspecified Positive     23 
Newman (1994) Nurses 24/25 Unspecified Positive 24 
Guinée EP (1991) Pharmacists  15/20  Unspecified Negative  26 
Thiringer (1991) Nurses 60/60 HFL Positive 19 
Krepinsky (1990) Nurses Unspecified Negative  27 
Elliot (1990) Pharmacists  6 Unspecified Negative 28 
Clonfero (1989) Nurses 9/11 No particular precaution Positive, SD 9 
Rossner (1988) Preparers 38/18 Unspecified Positive 29 
Caudell (1988) Nurses  No particular precaution 
Positive, 
SD 
8 
Poyen (1988) Nurses 47/37 HFL vertical Negative 4 
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Stucker (1986) Nurses  No particular precaution Positive, SD 7 
Pohlova (1986) 
Preparers  Chimists 
38/19 
No particular precaution Positive 30 
Friederich(1986) Nurses 24/ No particular precaution Doubtful 15 
Benhamou (1986) Nurses 29/29 No particular precaution Positive, SD 2 
Barale (1985) Nurses 21/21 Unspecified negative  31 
Everson (1985) 
Nurses Pharmacists  
26/38 
LFH approprate protection  Negative 3 
Venitt (1984) Nurses LFH horizontal   Negative 32 
Ratcliffe (1983) Nurses LFH vertical Negative 
 
33 
Kolmodinhedman(1983) Nurses Hood and gloves  Positive, SD 10 
Anderson (1982) 
Nurses 
Pharmacists  6 
LFH vertical,                       
LFH horizontal Positive 
18 
Bos (1982) Nurses Unspecified Doubtful 14 
Staiainio (1981) Nurses LFH vertical ou horizontal  Negative 
 
34 
Falck (1979) Nurses No particular precaution Positive, SD 1 
 
*Ref:reference  LFH: laminar flow hood SD: significant difference  
 
Conclusion  
This study confirms the mutagenic cytostatic risk in the population of workers handling these drugs in the absence 
of adequate safeguards. It suggests alignment with best practices for improving working conditions in oncology 
structures. This is particularly the biannual special medical supervision, centralization of preparations in the URC, 
the staffing of personal protection means and staff training on occupational hazards. . 
 
No Conflict Of Interest 
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